anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Four focus groups will be conducted in three community centers (n=6 to 8 participants/group; n=28 participants). First, all participants will read and sign the consent form. They will also complete a sociodemographic questionnaire. Then, the moderator will conduct the discussion using a semi-structured interview guide, based on the construct of the Theory of Planned Behaviour. The interview guide has been developed to identify the beliefs that determine the participants' attitudes (advantages/disadvantages), subjective norms (approval/disapproval of important others) and perceived behavioral control (facilitators/barriers) related to a hypothetical participation in the NutriQuébec study. The participants will also be questioned about their preferences regarding the recruitment as well as their concerns about the security, use and share of data. The focus groups will be recorded and transcribed. Two coders will perform the codification independently using NVivo 10.
Autosomal recessive cerebellar ataxias (ARCAs) are inherited neurological disorders that can affect both the central and peripheral nervous systems. To assess the effects of interventions according to the perception of people affected, patient-reported outcome measures (PROMs) must be available. This paper presents the development process of the Person-Reported Ataxia Impact Scale (PRAIS), a new PROM in recessive ataxias, and the documentation of its content validity, interpretability, and construct validity (structural and discriminant). The development followed the PROMIS framework and the Food and Drug Administration guidelines. A mixed-method study design was used to develop the PROM. A systematic review of the literature, semistructured interviews, and discussion groups was conducted to constitute an item pool. Experts' consultation helped formulate items, and the questionnaire was sent online to be completed by people affected. Statistical analyses were performed to assess the structural and discriminant validity. A total of 125 people affected by recessive ataxia completed the questionnaire. The factor analysis confirmed the three components: physical functions and activities, mental functions, and social functions. The statistical analysis showed that it can discriminate between stages of mobility and level of autonomy. It showed very good levels of internal consistency (0.79 to 0.89). The Person-Reported Ataxia Impact Scale (PRAIS) is a 38-item questionnaire that assesses the manifestations and impacts of the disease according to the perception of people affected by recessive ataxia. It can be used in clinical and research settings.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

SPORANOX ® has been associated with rare cases of serious hepatotoxicity, including liver failure and death. Some of these cases had neither pre-existing liver disease nor a serious underlying medical condition. If clinical signs or symptoms develop that are consistent with liver disease, treatment should be discontinued and liver function testing performed. The risks and benefits of SPORANOX ® use should be reassessed. (See WARNINGS: Hepatic Effects and PRECAUTIONS: Hepatotoxicity and Information for Patients.)
Rapid expansion of the pulmonary microvasculature through angiogenesis drives alveolarization, the final stage of lung development that occurs postnatally and dramatically increases lung gas-exchange surface area. Disruption of pulmonary angiogenesis induces long-term structural and physiologic lung abnormalities, including bronchopulmonary dysplasia, a disease characterized by compromised alveolarization. Although endothelial cells are primary determinants of pulmonary angiogenesis, mesenchymal cells (MC) play a critical and dual role in angiogenesis and alveolarization. Therefore, we performed single cell transcriptomics and in-situ imaging of the developing lung to profile mesenchymal cells during alveolarization and in the context of lung injury. Specific mesenchymal cell subtypes were present at birth with increasing diversity during alveolarization even while expressing a distinct transcriptomic profile from more mature correlates. Hyperoxia arrested the transcriptomic progression of the MC, revealed differential cell subtype vulnerability with pericytes and myofibroblasts most affected, altered cell to cell communication, and led to the emergence of Acta1 expressing cells. These insights hold the promise of targeted treatment for neonatal lung disease, which remains a major cause of infant morbidity and mortality across the world.
PURPOSE: Provided are the extract of Sambucus williamsii var. coreana Nakai, Sambucus sieboldiana var. pendula(Nakai.)T. Lee, and Sambucus sieboldiana Blume which inhibits activity of cathepsin K and a method for extracting the same. Also, provided is a composition containing the extract as an active ingredient. CONSTITUTION: The extract having inhibiting effect on the activity of cathepsin K is obtained by extracting one or two of Sambucus williamsii var. coreana Nakai, Sambucus sieboldiana var. pendula(Nakai.)T. Lee, and Sambucus sieboldiana Blume. The composition of functional foods or drugs for prevention and treatment of osteoporosis is characterized by containing the extract as an active ingredient. The extract is obtained by adding distilled water to one or two of Sambucus williamsii var. coreana Nakai, Sambucus sieboldiana var. pendula(Nakai.)T. Lee, and Sambucus sieboldiana Blume, followed by heating to 80-100 deg.C; centrifuging the heated solution to give supernatant; and freeze-drying the supernatant.
Currently there is wide variation in practice and little evidence to guide the treatment of early cryptococcal infection in HIV-infected individuals with advanced immunosuppression. However, epidemiologic studies suggest that this may be a promising novel approach to decrease the mortality due to cryptococcal meningitis (CM), the second leading cause of death among HIV-infected individuals in many resource-limited settings. Screening asymptomatic HIV-infected individuals with advanced immunosuppression for serum cryptococcal antigen (CrAg) clearly identifies a population at high risk of CM and death and is a feasible screening method for resource-limited settings. However, screening with serum CrAg alone without additional diagnostic studies identifies a heterogeneous clinical population with early cryptococcal infection, many of whom already have sub-clinical meningeal infection or fungemia. The mainstay of anti-cryptococcal therapy in resource-limited settings is oral fluconazole though preliminary evidence suggests this is not an effective treatment. Thus, there is a critical need for potent therapies that (1) can be safely administered in resource-limited settings and (2) are effective in a heterogeneous population of HIV-infected individuals with advanced immunosuppression and early cryptococcal infection who are initiating anti-retroviral therapy (ART).

This single center, open-label, randomized Phase IIb study is being conducted to assess the safety and estimate the efficacy of oral fluconazole in combination with flucytosine for the treatment of early cryptococcal infection. The study will be based at two sites supported by Family AIDS Care and Education Services (FACES) in Western Kenya. A consecutive sample of 100 HIV-infected adults with CD4 cell count ≤100 cells/µl and serum CrAg titer ≥1:2 who have no signs or symptoms of severe, systemic cryptococcal infection will be enrolled. At enrollment, specimens from participants will be cultured for evidence of Cryptococcus neoformans. Individuals who meet inclusion and exclusion criteria and consent to participate in the study will be randomized to combination therapy with oral fluconazole (1200mg/day) plus flucytosine (100mg/kg/day) or fluconazole alone for the fourteen days of therapy. Subsequently both groups will receive anti-retroviral therapy as well as fluconazole 800mg/day for 8 weeks followed by 200mg/day. The primary safety endpoint will be the incidence of treatment-related adverse events and serious adverse events. The primary efficacy endpoint will be survival at 12 weeks.

In addition, we will offer additional diagnostic testing and aim for 50% participation, approximately 25 individuals from each arm. We will perform a battery of diagnostic tests including chest radiography, fungal cultures in blood, sputum, urine, stool and cerebrospinal fluid (CSF), cryptococcal antigen testing in the CSF, and gram stain, Ziehls-Nielsen stain and India Ink staining of CSF sediment. Anti-fungal susceptibility testing via broth microdilution and polymerase chain reaction serotyping and mating type analysis will be performed on clinical isolates.
The invention relates to a lovastatin capsule and a preparation method thereof. The lovastatin capsule comprises 20 parts of lovastatin, 50-200 parts of low-substituted hydroxypropyl cellulose, 1-10 parts of polyvinyl polypyrrolidone, 1-5 parts of lauryl sodium sulfate, 1-10 parts of povidone K30 and 1-30 parts of magnesium stearate. The lovastatin capsule disclosed by the invention can be used for reducing blood fat. The lovastatin capsule disclosed by the invention is reasonable in prescription, feasible in process, stable and reliable in quality, and relatively good in stability, dissolution rate and bioavailability. The lovastatin capsule is prepared by adopting a wet-process granulation process, a method of adding a solubilizer lauryl sodium sulfate is proper, adhesive concentration is proper, and therefore, the lovastatin capsule belongs to powder with relatively good liquidity, and can satisfy capsules filling needs. Besides, the lovastatin capsule is short in production period, low in production cost and easy for industrial production.
The invention provides scaffolds, methods of culturing cells on and/or within scaffolds, and methods of making scaffolds, wherein the scaffolding comprises thermoresponsive polymers,  e.g. , N-isopropylacrylamide (NIPAAm). The scaffolds may include other polymers, cell adhesion factors, polymers that are not NIPAAm, and/or cells. The scaffold also exhibits a phase transition in solution above a lower critical solution temperature (LCST). The scaffolds form structures such as beads and/or threads. The scaffolds can be incorporated into tissue cultures vessels. Also provided are methods for recovering cells cultured on the scaffolds by lowering the temperature below an LCST.
Neonatal hyperbilirubinemia or newborn jaundice impacts over 85% of all newborns \[1\]. Regardless of the mechanism, excessive hyperbilirubinemia has been traditionally treated with phototherapy to minimize any probable risk of developing bilirubin-induced neurotoxicity. However, earlier and more recent data suggest that pre-discharge bilirubin screening for risk of significant hyperbilirubinemia, whether due to a rapid bilirubin production or an earlier age of onset, has impacted the guidelines for clinical use of phototherapy \[1, 2\]. In this study, we plan to test the performance of a novel transcutaneous device (BiliCareTM) first for screening for bilirubin levels at postnatal age of 6 to 48 hrs; and possibly also, to substitute the use of this measurement for total plasma/serum bilirubin (TB). This device applies a novel light transmission technology that has the potential to measure bilirubin as a point-of-care test in the subcutaneous tissue, and then uses an internal algorithm to calculate bilirubin levels in the skin. In this proposalstudy, we will to assess the clinical performance of the BiliCare by correlating measurements made by this device to near-concurrent measure of total plasma/serum bilirubin at normative ranges (mean, median, range and inter-quartile ranges ) for all term and late-preterm newborns (including those who are at-risk for jaundice and / or being administered with phototherapy) born to families of diverse race and ethnic backgrounds.
AIM: Previous studies have shown that fenofibrate improves outcomes such as albuminuria and estimated glomerular filtration rate decline. We hypothesize that fenofibrate has renoprotective effects and prevents or delays the development of end-stage renal disease. The objective of this study is to investigate the risk of incident end-stage renal disease in relation to fenofibrate treatment in patients who are already taking statins.
MATERIALS AND METHODS: We performed a nationwide population-based cohort study using data from the Korea National Health Information Database from 2010 to 2017. Among adults using statins, 413 715 fenofibrate users were compared with 413 715 fenofibrate non-users after 1:1 age, sex and triglyceride matching. The endpoint of this study was incident end-stage renal disease.
RESULTS: During a median 3.96-year follow-up, the incidence per 1000 person years of end-stage renal disease was lower in fenofibrate users than in fenofibrate non-users (0.885 vs. 0.960, p < 0.0001). The hazard ratio for end-stage renal disease was lower (0.763, 95% confidence interval 0.710-0.821) in fenofibrate users. This association was significant in patients with hypertension, proteinuria and an estimated glomerular filtration rate <60 mL/min/1.732.
CONCLUSIONS: Fenofibrate use in patients taking statins with either hypertension, proteinuria, or decreased estimated glomerular filtration rate is associated with a low risk of incident end-stage renal disease. To confirm the renoprotective effect of fenofibrate in chronic kidney disease, a randomized controlled trial is warranted.
PURPOSE: To describe the innovative technique of trocar-assisted intraocular lens (IOL) and capsular bag complex fixation.
METHODS: In this technique, initial pupil dilatation is achieved either with intracameral adrenaline or with the help of iris hooks. Automated anterior vitrectomy is performed in cases with vitreous prolapse. A 25 G trocar cannula is placed at the limbus through a paracentesis opposite the zonular dialysis area. The cannula lumen act as a guide to pass the double-arm polypropylene suture attached to the needle. This prevents any inadvertent corneal injury and acts as a perpendicular tract to pass the needle through IOL capsular bag complex.
RESULTS: We performed this technique in 9 cases with an excellent outcome with a minimum of 3 months of follow-up. All patients had well-centred IOL. There was no incidence of corneal injury, Descemet membrane detachment, iris trauma, IOL tilt, decentration, dislocation, vitreous prolapse or retinal detachment. All patients achieved excellent visual acuity ranging from 6/12-6/6 postoperatively.
CONCLUSION: The novel trocar-assisted IOL bag complex fixation technique is very effective and allows smooth IOL fixation in technically challenging cases with IOL subluxation. The trocar acts as a guide to prevent injury to the surrounding tissue, and IOL fixation is achieved with minimal manipulations in the anterior chamber. It also prevents the need for IOL explantation in these cases.
The recommended adult dosage of mesalamine rectal suspension enema in 60 mL units is one rectal instillation (4 grams) once a day, preferably at bedtime, and retained for approximately eight hours. While the effect of mesalamine rectal suspension enema may be seen within 3 to 21 days, the usual course of therapy would be from 3 to 6 weeks depending on symptoms and sigmoidoscopic findings. Studies available to date have not assessed if mesalamine rectal suspension enema will modify relapse rates after the 6-week short-term treatment. Mesalamine rectal suspension enema is for rectal use only.

Drink an adequate amount of fluids during treatment.

Patients should be instructed to shake the bottle well to make sure the suspension is homogeneous. The patient should remove the protective sheath from the applicator tip. Holding the bottle at the neck will not cause any of the medication to be discharged. The position most often used is obtained by lying on the left side (to facilitate migration into the sigmoid colon); with the lower leg extended and the upper right leg flexed forward for balance. An alternative is the knee-chest position. The applicator tip should be gently inserted in the rectum pointing toward the umbilicus. A steady squeezing of the bottle will discharge most of the preparation. The preparation should be taken at bedtime with the objective of retaining it all night. Patient instructions are included with every seven units.
Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV beginning 1 hour into leucovorin calcium infusion weekly for 6 weeks. Treatment is repeated every 8 weeks for 4 courses.
PURPOSE: To obtain a readily splittable tablet capable of preventing bonding with a film coating by forming each constricted part in the same vertical cross section from plural wholly curved split units having the top and bottom protruding surfaces and further integrating the split units. CONSTITUTION: This splittable tablet 1 has plural split units 2 prepared by forming the vertical cross-sectional shape of the top surface 3 and the undersurface 4 thereof into a protruding and wholly curved shape and is obtained by forming each curved constricted part 10 in the top surface 3 and the undersurface 4 on the same vertical cross section and integrally molding the whole comprising the bonded split units 2. Since each constricted part 10 of the top surface 3 and the undersurface 4 of the tablet 1 is formed on the same vertical cross section, the fractured section coincides with the same vertical cross section. Thereby, the objective tablet of an accurate dosage unit is obtained. Since the contact area of the tablet can be reduced, the mutual tablets 1 can be prevented from bonding in a film coating process.  Furthermore, the constricted part 10 is preferably formed on the same vertical cross section in not only the vertical directions but also the horizontal direction.
Implantable devices comprise at least one or more targeting molecules that form a primary coating layer for selectively recruiting, isolating, activating, and/or eliminating any cells of interest, such as T cells, monocytes, and stem cells. The implantable devices can be utilized for selectively removing a particular subset of cells from bodily fluids of a patient. Various non-selective pharmaceutical agents and biological agents can be incorporated into the implantable devices so that cells of interest can be isolated for elimination or for activation/differentiation. Cell-type selectivity is conferred by the presence of cell-type-specific targeting molecules incorporated into the implantable device, preferably at the surface level to permit direct or indirect interaction between the cells of interest and targeting molecules of the implantable device. Related therapeutic methods for utilizing the implantable devices are also provided. These implantable devices can be manufactured as a stent, a catheter, a holding chamber, or any other device, and can be manufactured into any shape, including a conduit, a vessel, and a tubing.
A method for preparing the extract of Fatsia japonica root barks is provided to optimize the extraction conditions and enhance the immune activity functions of the Fatsia japonica root bark extract. The method for preparing the extract of Fatsia japonica root barks comprises the steps of: dipping the pulverized Fatsia japonica root barks in ethanol at 20-25 deg. C for 12 hours; extracting them in ethanol at 35-45 deg. C for 12 hours; dipping them in ethanol at 20-25 deg. C for 12 hours; extracting them in ethanol at 55-65 deg. C for 12 hours; filtering the extract of Fatsia japonica root barks and concentrating it at 40-50 deg. C under reduced pressure; and freeze-drying the concentrate.
1. Technical Result Possibility of modulating body weight of animals, mammalians including humans.          2. Essence The present invention relates to nucleotide sequences and proteins, which are expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The mentioned nucleotide sequences correspond to the murine and human OB gene, which plays a critical role in the regulation of body weight and adiposity. By the preliminary data, the polypeptide of said gene is functioning as a hormone. The present invention further provides nucleic acid molecules for use as molecular probes or as primers for polymerase chain reaction (PCR) amplification or synthesis or natural oligonucleotides of the control vector, which comprises the mentioned nucleic acids. and bacterial insects expression vector or mammalian expression vector with the mentioned nucleic acids, which are operatively connected to the nucleotide sequences control. The invention further relates to host cells transfected or transformed with an appropriate expression vector and to their use in the preparation of the modulators of the invention. Also provided are antibodies to the OB polypeptide, methods for modulating body weight of a mammal and in special examples the genes, which effect coding of murine and human OB gene, and two isoforms thereof.          3. Field of Application Medicine, diagnostics and therapy.
After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx or Carto system), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.